<DOC>
	<DOCNO>NCT01648829</DOCNO>
	<brief_summary>Levels platelet reactivity patient Dual Antiplatelet Therapy ( DAPT ) influence concomitant treatment medication ( i.e . statin ) inhibit CYP3A4 system involve activation clopidogrel . Atorvastatin simvastatin metabolize CYP3A4 . Pitavastatin , unlike statin , little metabolized , dose excrete unchanged bile , biotransformation cytochrome P450 system minimal . Indeed , pitavastatin 's cyclopropyl group divert drug away metabolism CYP3A4 allow small amount clinically insignificant metabolism CYP2C9 . The primary objective study compare pharmacodynamic effect CYP3A4-metabolized statin ( atorvastatin ) versus non-CYP3A4-metabolized statin ( pitavastatin ) patient show high platelet reactivity DAPT .</brief_summary>
	<brief_title>PharmacOdynamic compaRison piTavastatin Versus atOrvastatin Platelet Reactivity</brief_title>
	<detailed_description>Patients coronary artery disease ( CAD ) often treat dual anti-platelet therapy ( DAPT ) , include aspirin clopidogrel , prevent recurrent atherothrombotic event . Levels platelet reactivity patient DAPT influence concomitant treatment medication ( i.e . statin ) inhibit CYP3A4 system involve activation clopidogrel . Atorvastatin simvastatin metabolize CYP3A4 . Pitavastatin , unlike statin , little metabolized , dose excrete unchanged bile , biotransformation cytochrome P450 system minimal . Indeed , pitavastatin 's cyclopropyl group divert drug away metabolism CYP3A4 allow small amount clinically insignificant metabolism CYP2C9 . At least 1 month start DAT ( clopidogrel 75 mg aspirin 100 mg ) , patient receive randomly atorvastatin ( 20 mg day , N=50 ) pitavastatin ( 4 mg day , N=50 ) 30 day ( T-1 ) . At time-point , wash-out period 15 day first treatment atorvastatin pitavastatin order avoid carry-over effect . Afterwards , cross-over perform , patient switch drug continue 30 day ( T-2 ) . No previous study evaluate influence pitavastatin compare statin platelet reactivity patient receive DAPT . The primary objective study compare pharmacodynamic effect CYP3A4-metabolized statin ( atorvastatin ) versus non-CYP3A4-metabolized statin ( pitavastatin ) patient show high platelet reactivity DAPT .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Angiographicallyproven coronary artery disease Class I indication DAT recent ( &lt; 12 month ) percutaneous coronary intervention and/or recent acute coronary syndrome ( &lt; 12 month ) Stable clinical condition Able understand willing sign inform CF Use drug interfere CYP activity proton pump inhibitor Women child bear potential patient must demonstrate negative pregnancy test perform within 24 hour CT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>